Skip to main content
Fig. 4 | Journal of Hematology & Oncology

Fig. 4

From: AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways

Fig. 4

The impact of AC-93253 iodide on cell motility and drug synergism. a Inhibitory effects of AC-93253 iodide on cancer cell invasion as determined by the transwell assay with Matrigel. b Inhibitory effects of AC-93253 iodide on cancer cell migration as determined by the transwell assay without Matrigel. c Synergistic effects of AC-93253 iodide and gefitinib on gefitinib-resistant lung adenocarcinoma cells determined by cell viability assay. The indicated combinations of AC-93253 iodide and gefitinib were used to treat lung adenocarcinoma A549, PC9/gef, and H1975 cells for 72 h. The CI was calculated using the data and CalcuSyn software. Each experiment was performed independently and was repeated three times. *P < 0.05 compared with control (0 nM; 0.1% DMSO)

Back to article page